# Caligan Partners LP 13F holdings Q2 2026: $2.1 billion

Caligan Partners LP reported $2.1 billion in 13F securities across 28 positions for the quarter ended June 30, 2026, in a holdings report filed August 14, 2026. Its largest holding was Liquidia Corporation at $647 million, 30.5% of the reported value. Since Q1 2026 it opened 5 new positions and exited 5.

SpecStream is the live web data engine for teams and agents. It reads the SEC's Form 13F data sets each quarter, and this page is that reading, keyed on the manager's CIK and the security's CUSIP. Ask for the managers or the holdings you track, and each new 13F filing arrives in your sheet, CRM, Slack or agent as the SEC publishes it.

- Quarter: Q2 2026, the quarter ended June 30, 2026
- Reported value: $2,125,706,950
- Positions: 28
- Filed: August 14, 2026
- Report type: 13F holdings report
- CIK: 1727492
- Form 13F file number: 028-23096
- CRD number: 289887
- Business address: 780 Third Avenue 30th Floor, New York, NY 10017
- SEC filing: [0001420506-26-001809](https://www.sec.gov/Archives/edgar/data/1727492/000142050626001809/0001420506-26-001809-index.htm)
- Investment adviser record: [Form ADV on SpecStream](https://specstream.ai/data/investment-advisers/firm/caligan-partners-289887)

## Top 25 holdings by value

The largest of 28 positions by reported value at the end of the quarter ended June 30, 2026. Put and call options are marked in the class. Change is in shares or principal against the filing for the quarter ended March 31, 2026.

| Issuer | Class | Shares or principal | Value | Change since Q1 2026 |
| --- | --- | --- | --- | --- |
| [Liquidia Corporation](https://specstream.ai/data/institutional-holders/liquidia-corporation-53635d202) | COM NEW | 8,118,892 | $647.3 million | No change |
| [Revolution Medicines Inc](https://specstream.ai/data/institutional-holders/revolution-medicines-inc-76155x100) | COM | 1,961,795 | $367.4 million | +308,987 |
| [Abivax SA](https://specstream.ai/data/institutional-holders/abivax-sa-00370m103) | SPONSORED ADS | 1,557,924 | $207.6 million | +96,000 |
| [Vaxcyte Inc](https://specstream.ai/data/institutional-holders/vaxcyte-inc-92243g108) | COM | 2,188,636 | $127.2 million | +127,917 |
| [Exelixis Inc](https://specstream.ai/data/institutional-holders/exelixis-inc-30161q104) | COM | 1,553,262 | $84.5 million | No change |
| [Tango Therapeutics Inc](https://specstream.ai/data/institutional-holders/tango-therapeutics-inc-87583x109) | COM | 2,500,103 | $78.2 million | +91,305 |
| [Avalo Therapeutics Inc](https://specstream.ai/data/institutional-holders/avalo-therapeutics-inc-05338f306) | COM NEW | 3,163,866 | $58.5 million | +1,528,843 |
| [Xenon Pharmaceuticals Inc](https://specstream.ai/data/institutional-holders/xenon-pharmaceuticals-inc-98420n105) | COM | 889,944 | $53.7 million | -503,083 |
| [Adma Biologics Inc](https://specstream.ai/data/institutional-holders/adma-biologics-inc-000899104) | COM | 5,725,007 | $47.9 million | +968,496 |
| Revolution Medicines Inc | COM (call) | 251,800 | $47.2 million | +22,900 |
| [LB Pharmaceuticals Inc](https://specstream.ai/data/institutional-holders/lb-pharmaceuticals-inc-50180m108) | COM SHS | 1,438,070 | $46.7 million | No change |
| [Immunocore Hldgs PLC](https://specstream.ai/data/institutional-holders/immunocore-hldgs-plc-45258d105) | ADS | 1,381,317 | $43.9 million | New |
| [Viridian Therapeutics Inc](https://specstream.ai/data/institutional-holders/viridian-therapeutics-inc-92790c104) | COM | 2,193,981 | $40.3 million | New |
| [Vor Biopharma Inc](https://specstream.ai/data/institutional-holders/vor-biopharma-inc-929033207) | COM NEW | 1,925,066 | $35.4 million | No change |
| [Sab Biotherapeutics Inc](https://specstream.ai/data/institutional-holders/sab-biotherapeutics-inc-78397t202) | COM NEW | 7,967,207 | $31.1 million | No change |
| [Inventiva SA](https://specstream.ai/data/institutional-holders/inventiva-sa-46124u107) | ADS | 8,163,191 | $30.9 million | +3,188,285 |
| [Aura Biosciences Inc](https://specstream.ai/data/institutional-holders/aura-biosciences-inc-05153u107) | COM | 4,298,248 | $30.5 million | +4,068,384 |
| [Tyra Biosciences Inc](https://specstream.ai/data/institutional-holders/tyra-biosciences-inc-90240b106) | COM | 806,986 | $25.8 million | -469,982 |
| [Opus Genetics Inc](https://specstream.ai/data/institutional-holders/opus-genetics-inc-67577r102) | COM | 6,077,084 | $25 million | +2,056 |
| [Anika Therapeutics Inc](https://specstream.ai/data/institutional-holders/anika-therapeutics-inc-035255108) | COM | 1,435,130 | $21 million | No change |
| [Sagimet Biosciences Inc](https://specstream.ai/data/institutional-holders/sagimet-biosciences-inc-786700104) | COM SER A | 2,500,000 | $19.3 million | New |
| [Artiva Biotherapeutics Inc](https://specstream.ai/data/institutional-holders/artiva-biotherapeutics-inc-04317a107) | COM | 1,736,111 | $16.8 million | New |
| [Faeth Therapeutics Inc](https://specstream.ai/data/institutional-holders/faeth-therapeutics-inc-81728a207) | COM NEW | 629,467 | $15.7 million | +503,465 |
| [MBX Biosciences Inc](https://specstream.ai/data/institutional-holders/mbx-biosciences-inc-55287l101) | COM | 200,000 | $11 million | -648,590 |
| [Verrica Pharmaceuticals Inc](https://specstream.ai/data/institutional-holders/verrica-pharmaceuticals-inc-92511w207) | COM SHS | 923,910 | $5.7 million | No change |

## New positions in Q2 2026

5 positions not in the filing for the quarter ended March 31, 2026.

| Issuer | Class | Shares or principal | Value |
| --- | --- | --- | --- |
| [Immunocore Hldgs PLC](https://specstream.ai/data/institutional-holders/immunocore-hldgs-plc-45258d105) | ADS | 1,381,317 | $43.9 million |
| [Viridian Therapeutics Inc](https://specstream.ai/data/institutional-holders/viridian-therapeutics-inc-92790c104) | COM | 2,193,981 | $40.3 million |
| [Sagimet Biosciences Inc](https://specstream.ai/data/institutional-holders/sagimet-biosciences-inc-786700104) | COM SER A | 2,500,000 | $19.3 million |
| [Artiva Biotherapeutics Inc](https://specstream.ai/data/institutional-holders/artiva-biotherapeutics-inc-04317a107) | COM | 1,736,111 | $16.8 million |
| [Cellectar Biosciences Inc](https://specstream.ai/data/institutional-holders/cellectar-biosciences-inc-15117f880) | COM NEW | 469,998 | $1.3 million |

## Positions exited in Q2 2026

5 positions in the filing for the quarter ended March 31, 2026 and not in this one, with the shares and value reported then.

| Issuer | Class | Shares or principal | Value |
| --- | --- | --- | --- |
| [Mineralys Therapeutics Inc](https://specstream.ai/data/institutional-holders/mineralys-therapeutics-inc-603170101) | COM | 2,772,654 | $75.1 million |
| CG Oncology Inc | COM (call) | 900,000 | $60.9 million |
| [Spyre Therapeutics Inc](https://specstream.ai/data/institutional-holders/spyre-therapeutics-inc-00773j202) | COM NEW | 878,127 | $44.3 million |
| [Maze Therapeutics Inc](https://specstream.ai/data/institutional-holders/maze-therapeutics-inc-578784100) | COM | 614,962 | $18.4 million |
| [Xilio Therapeutics Inc](https://specstream.ai/data/institutional-holders/xilio-therapeutics-inc-98422t209) | COM | 112,128 | $942,996 |

## Also on SpecStream

- [Caligan Partners LP Form 13F filing on EDGAR](https://www.sec.gov/Archives/edgar/data/1727492/000142050626001809/0001420506-26-001809-index.htm)
- [Caligan Partners LP investment adviser record (Form ADV)](https://specstream.ai/data/investment-advisers/firm/caligan-partners-289887)
- [Largest 13F filers in New York](https://specstream.ai/data/institutional-holdings/state/new-york)
- [Largest institutional managers by 13F value](https://specstream.ai/data/institutional-holdings)
- [Most widely held securities in 13F filings](https://specstream.ai/data/institutional-holders)

Source: [the SEC's Form 13F data sets](https://www.sec.gov/data-research/sec-markets-data/form-13f-data-sets). Public data published by the US Securities and Exchange Commission (US government work). Managers report these holdings themselves in Form 13F, and the SEC does not check or guarantee them. Form 13F lists long positions in US listed equities, some options and convertible notes held at the end of the quarter, and leaves out short positions, cash, most bonds and holdings below the reporting threshold. Values are market values in US dollars as the manager filed them. A manager can ask the SEC to keep some positions confidential for a time. This page uses SEC data and is not endorsed or certified by the SEC.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in New York, New York

- [Middle schools in New York, New York](https://specstream.ai/data/businesses/middle-schools/new-york-new-york-united-states)
- [Carpenters in New York, New York](https://specstream.ai/data/businesses/carpenters/new-york-new-york-united-states)
- [Pediatric clinics in New York, New York](https://specstream.ai/data/businesses/pediatric-clinics/new-york-new-york-united-states)
- [Cosmetology schools in New York, New York](https://specstream.ai/data/businesses/cosmetology-schools/new-york-new-york-united-states)
- [Public relations firms in New York, New York](https://specstream.ai/data/businesses/public-relations-firms/new-york-new-york-united-states)
- [Ear, nose and throat clinics in New York, New York](https://specstream.ai/data/businesses/ear-nose-and-throat-clinics/new-york-new-york-united-states)
